Loading
AW
American Well Corp Stock: price and insider trades · United States
American Well Corp: what insiders have been doing
American Well Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 45 filings signed by 14 insiders.
Only sales appear on the open market, 28 sales in all totalling €676k, filed by 6 insiders. The totals do not cover 5 filings with an undisclosed amount. Hirschhorn Mark filed the largest sale, €109k, on 3 September 2026, which represents 0.055% of the company's market value.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 45 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 5 purchases and 294 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 249.3 m USD and net income at -95.7 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
386
Thresholds
n/a
Buy Volume
€1M
5 ops. · all time
Sell Volume
€27M
294 ops. · all time
Who traded when
BuySalePaul Francis McNeice18 sales
Phyllis Gotlib18 sales
Dmitry Zamansky6 sales
Mark Hirschhorn5 sales
Deborah C. Jackson4 sales
Knight Kurt2 sales
+3 other insiders
Analyst consensus: bullish or bearish?
Analysts rate American Well Corp Hold (neutral), based on 5 analysts. Average price target: US$12.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,666 of 24,148 companies
17.6
score / 100
Value6
Quality29
FCF yld-32%
Earn yld-46%
EV/EBITDA·
ROE-29%
Gross mgn53%
Net mgn-38%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.38
Analyst consensus
5 analystsHold
US$11.00Target US$12.80(+3%)US$16.00
Income statement
RevenueUS$249.3M
Gross profitUS$132.9M53% margin
EBITDA-US$71.3M-29% margin
Net income-US$95.7M-35.7% margin
Valuation
PER (forward)-7.8x
P/Book0.9x
Beta1.68
Balance sheet & cash
Market capUS$206.9M
Total debtUS$4.5M
Free Cash Flow-US$66M
Debt / Equity1%
Profitability & ownership
ROE-29.1%
ROA-12.6%
% insiders4.6%
% institutions47.5%
Last declaration on 5 October 2026
Declarations386 total
653 shares@ US$13.000.0038% mcap7.8% of flowClass A Common StockSEC:0001714025-26-000003:0
4,282 shares@ US$13.000.025% mcap16.6% of flowClass A Common StockSEC:0001081343-26-000004:0
8,442 shares@ US$13.000.050% mcap31.4% of flowClass A Common StockSEC:0002059643-26-000004:0
6,677 shares@ US$13.000.039% mcap5.1% of flowClass A Common StockSEC:0001824038-26-000004:0
8,442 shares@ US$13.00050.050% mcap58.3% of flowClass A Common StockSEC144:0001193125-26-410807
4,282 shares@ US$13.00050.025% mcap58.2% of flowClass A Common StockSEC144:0001193125-26-410841
6,677 shares@ US$13.00050.039% mcap58.3% of flowClass A Common StockSEC144:0001193125-26-410796
112 shares@ US$11.800.0006% mcap1.3% of flowClass A Common StockSEC:0001193125-26-382066:0
3,573 shares@ US$11.800.018% mcap2.5% of flowClass A Common StockSEC:0001193125-26-382072:0
10,751 shares@ US$11.800.055% mcap44.1% of flowClass A Common StockSEC:0001193125-26-382079:0
8,460 shares@ US$9.33150.035% mcap100.0% of flowClass A Common StockSEC144:0001193125-26-292768
4,299 shares@ US$9.33150.018% mcap100.0% of flowClass A Common StockSEC144:0001193125-26-292784
6,677 shares@ US$9.33150.028% mcap100.0% of flowClass A Common StockSEC144:0001193125-26-292747
6,677 sharesClass A Common StockSEC:0001193125-26-292804:0
8,460 sharesClass A Common StockSEC:0001193125-26-292828:0
4,299 sharesClass A Common StockSEC:0001193125-26-292835:0
653 sharesClass A Common StockSEC:0001193125-26-292842:0
14,501 sharesClass A Common StockSEC:0001193125-26-276095:0
14,501 sharesClass A Common StockSEC:0001193125-26-276113:0
14,501 sharesClass A Common StockSEC:0001193125-26-276120:0
14,501 sharesClass A Common StockSEC:0001193125-26-276140:0
14,501 sharesClass A Common StockSEC:0001193125-26-276145:0
14,501 sharesClass A Common StockSEC:0001193125-26-276107:0
9,750 sharesClass A Common StockSEC:0001193125-26-271312:0
9,750 shares@ US$8.42100.0% of flowCommonSEC144:0001950047-26-005945
25 of 386 declarations
About American Well Corp
American Well Corporation, which operates under the Amwell brand, is a US-listed digital health company traded on the NYSE under the ticker AMWL in the United States. The company was incorporated in Delaware in June 2006 and is headquartered in Boston, Massachusetts. Amwell’s core identity is that of an enterprise telehealth platform provider: it builds software and workflow infrastructure that allows health plans, hospitals, delivery networks, employers, retailers, and public-sector organizations to deliver virtual care at scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1393584/000095017025019024/amwl-20241231.htm?utm_source=openai))
From a business-model perspective, Amwell primarily monetizes a SaaS-based, technology-enabled care platform integrated into client workflows. Its solutions span a broad range of use cases, including urgent care, specialty care, behavioral health, chronic care, retail health, school-based care, and home-based care. The company’s offering combines live video visits, care coordination, administrative tools, and clinical-data integration; historically, it also marketed telehealth kiosks and related peripherals. For investors, the important distinction is that Amwell is not simply a consumer telemedicine app provider. It is positioned as an enterprise digital-care infrastructure vendor embedded in large healthcare ecosystems. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1393584/000095017025019024/amwl-20241231.htm?utm_source=openai))
Read moreShow less
In competitive terms, Amwell operates in a crowded telehealth market where pricing pressure, post-pandemic normalization of demand, and the need for deep workflow integration have become central. Its competitive advantages are tied to enterprise relationships, payer and provider distribution, and the ability to operate white-labeled solutions for large clients. The company has emphasized national-scale partnerships and a diversified client base, which supports its relevance in a market that remains highly fragmented and technically demanding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001393584/000095017025103029/amwl-ex99_1.htm?utm_source=openai))
Recent developments are important for assessing the stock. In early 2026, Amwell extended its relationship with Elevance Health through a renewed agreement under which it operates a white-labeled digital care delivery platform branded LiveHealth Online. In May 2026, the company reported first-quarter 2026 results via an SEC filing. Also, a May 6, 2026 filing disclosed that cofounder Roy Schoenberg resigned from the board effective immediately, marking a noteworthy governance change. Taken together, these updates suggest ongoing commercial continuity, but also an evolving leadership backdrop as execution and profitability remain key investor focus areas. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1393584/000119312526007807/amwl-20260105.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
